New drug shows promise for hard-to-treat stomach cancers with MET gene flaw
NCT ID NCT04923932
First seen May 13, 2026 · Last updated May 25, 2026 · Updated 1 time
Summary
This study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific gene change (MET amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants took the drug by mouth, and doctors measured tumor response using standard criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hopspital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.